4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE
Primary Progressive Aphasia
University of ChicagoSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Primary Progressive Aphasia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLORTAUCIPIR Mayo Clinic | Phase 4 | BBB |
Rotigotine I.R.C.C.S. Fondazione Santa Lucia | Phase 2 | B |
Nabilone Simon Ducharme, MD | Phase 2 | CCC |
FLUDEOXYGLUCOSE Mayo Clinic | Phase 1 | CC |
PITTSBURGH COMPOUND B UNLABELLED Mayo Clinic | Phase 1 | CC |
View all 9 →
Same molecule, other indications
4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →